 Dmitri Simberg
Concepts (339)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 31 | 2024 | 374 | 10.070 |
Why?
| | Liposomes | 19 | 2024 | 168 | 4.570 |
Why?
| | Complement Activation | 17 | 2025 | 376 | 4.120 |
Why?
| | Dextrans | 13 | 2024 | 82 | 3.910 |
Why?
| | Complement C3 | 10 | 2024 | 203 | 3.510 |
Why?
| | Polyethylene Glycols | 12 | 2025 | 601 | 3.300 |
Why?
| | Nanomedicine | 11 | 2024 | 31 | 3.260 |
Why?
| | Drug Delivery Systems | 16 | 2025 | 336 | 3.150 |
Why?
| | Doxorubicin | 6 | 2024 | 325 | 2.820 |
Why?
| | Complement System Proteins | 11 | 2024 | 313 | 2.270 |
Why?
| | Drug Carriers | 10 | 2024 | 118 | 2.240 |
Why?
| | Magnetite Nanoparticles | 9 | 2019 | 27 | 2.140 |
Why?
| | Ferric Compounds | 6 | 2016 | 47 | 2.050 |
Why?
| | Microbubbles | 7 | 2017 | 48 | 1.980 |
Why?
| | Neoplastic Cells, Circulating | 4 | 2017 | 71 | 1.770 |
Why?
| | Leukocytes | 5 | 2023 | 304 | 1.550 |
Why?
| | Macrophages | 8 | 2023 | 1480 | 1.550 |
Why?
| | Ferrosoferric Oxide | 4 | 2019 | 23 | 1.450 |
Why?
| | Mice, Inbred BALB C | 17 | 2021 | 1245 | 1.390 |
Why?
| | Receptors, Scavenger | 3 | 2016 | 21 | 1.290 |
Why?
| | Immunoglobulins | 3 | 2024 | 159 | 1.220 |
Why?
| | Scavenger Receptors, Class A | 3 | 2019 | 11 | 1.180 |
Why?
| | Immunoglobulin M | 3 | 2024 | 275 | 1.130 |
Why?
| | Opsonin Proteins | 2 | 2019 | 24 | 1.130 |
Why?
| | Cell Membrane | 4 | 2019 | 732 | 1.100 |
Why?
| | Cetuximab | 2 | 2018 | 94 | 1.080 |
Why?
| | Antibodies | 2 | 2019 | 398 | 1.070 |
Why?
| | Mice | 33 | 2025 | 16937 | 1.050 |
Why?
| | Animals | 47 | 2025 | 35360 | 1.050 |
Why?
| | Erythrocytes | 5 | 2019 | 672 | 1.010 |
Why?
| | Cell Separation | 2 | 2017 | 316 | 0.910 |
Why?
| | Immunoglobulin G | 3 | 2024 | 847 | 0.890 |
Why?
| | Antineoplastic Agents | 5 | 2019 | 2061 | 0.840 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2023 | 30 | 0.820 |
Why?
| | Lipids | 6 | 2022 | 625 | 0.810 |
Why?
| | Contrast Media | 3 | 2017 | 393 | 0.810 |
Why?
| | Receptors, Complement 3d | 1 | 2023 | 140 | 0.800 |
Why?
| | Endothelium | 2 | 2022 | 121 | 0.780 |
Why?
| | Cell-Penetrating Peptides | 2 | 2025 | 21 | 0.780 |
Why?
| | Neoplasms | 5 | 2024 | 2470 | 0.770 |
Why?
| | Click Chemistry | 2 | 2019 | 48 | 0.760 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2024 | 833 | 0.750 |
Why?
| | Phosphatidylethanolamines | 5 | 2014 | 74 | 0.750 |
Why?
| | Complement Pathway, Alternative | 3 | 2017 | 118 | 0.730 |
Why?
| | Fatty Acids, Monounsaturated | 5 | 2006 | 52 | 0.730 |
Why?
| | Quaternary Ammonium Compounds | 5 | 2006 | 53 | 0.730 |
Why?
| | Surface Properties | 7 | 2018 | 399 | 0.730 |
Why?
| | Blood Proteins | 4 | 2019 | 242 | 0.730 |
Why?
| | Fluorocarbons | 3 | 2013 | 109 | 0.670 |
Why?
| | Complement Inactivating Agents | 1 | 2020 | 45 | 0.660 |
Why?
| | Perfusion | 1 | 2020 | 197 | 0.650 |
Why?
| | Cell-Derived Microparticles | 1 | 2020 | 67 | 0.640 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 91 | 0.640 |
Why?
| | CD55 Antigens | 1 | 2019 | 29 | 0.630 |
Why?
| | Collagen Type II | 1 | 2019 | 47 | 0.630 |
Why?
| | Protein Corona | 1 | 2019 | 3 | 0.630 |
Why?
| | Cyclooctanes | 1 | 2018 | 5 | 0.620 |
Why?
| | Skin | 3 | 2020 | 725 | 0.620 |
Why?
| | Glioblastoma | 1 | 2022 | 326 | 0.620 |
Why?
| | Bone Marrow | 1 | 2020 | 271 | 0.620 |
Why?
| | Urinary Bladder | 2 | 2020 | 175 | 0.620 |
Why?
| | Lymphocytes | 2 | 2020 | 377 | 0.600 |
Why?
| | Cell Line, Tumor | 11 | 2022 | 3215 | 0.580 |
Why?
| | Transfection | 4 | 2005 | 911 | 0.570 |
Why?
| | Humans | 51 | 2025 | 129622 | 0.570 |
Why?
| | Antigens, Neoplasm | 4 | 2014 | 309 | 0.570 |
Why?
| | Intravital Microscopy | 1 | 2017 | 24 | 0.560 |
Why?
| | Monocytes | 1 | 2020 | 551 | 0.550 |
Why?
| | Biological Transport | 5 | 2020 | 401 | 0.550 |
Why?
| | Glioma | 1 | 2021 | 354 | 0.550 |
Why?
| | Skin Absorption | 1 | 2017 | 12 | 0.550 |
Why?
| | Protein Binding | 8 | 2019 | 2121 | 0.540 |
Why?
| | Phagocytes | 3 | 2023 | 97 | 0.540 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2017 | 123 | 0.540 |
Why?
| | Lipid Bilayers | 1 | 2018 | 98 | 0.540 |
Why?
| | Coated Materials, Biocompatible | 1 | 2016 | 59 | 0.520 |
Why?
| | Inflammation Mediators | 1 | 2019 | 505 | 0.520 |
Why?
| | Liver | 3 | 2023 | 1839 | 0.520 |
Why?
| | Particle Size | 5 | 2018 | 355 | 0.520 |
Why?
| | Mucous Membrane | 1 | 2017 | 122 | 0.520 |
Why?
| | Spectrometry, Fluorescence | 1 | 2017 | 171 | 0.510 |
Why?
| | Superoxide Dismutase | 1 | 2018 | 342 | 0.490 |
Why?
| | Fluorescent Dyes | 6 | 2021 | 317 | 0.490 |
Why?
| | Neovascularization, Pathologic | 2 | 2015 | 297 | 0.490 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2015 | 74 | 0.480 |
Why?
| | Arthritis, Rheumatoid | 2 | 2025 | 1092 | 0.470 |
Why?
| | Macrophages, Alveolar | 1 | 2018 | 389 | 0.470 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 181 | 0.460 |
Why?
| | Neutrophils | 1 | 2020 | 1205 | 0.460 |
Why?
| | Ligands | 2 | 2014 | 622 | 0.460 |
Why?
| | Immunomagnetic Separation | 1 | 2013 | 3 | 0.420 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1171 | 0.420 |
Why?
| | Polymers | 1 | 2017 | 479 | 0.420 |
Why?
| | Tissue Distribution | 4 | 2017 | 315 | 0.410 |
Why?
| | Mice, Inbred C57BL | 9 | 2021 | 5440 | 0.400 |
Why?
| | Complement C1q | 3 | 2022 | 37 | 0.390 |
Why?
| | Epithelial Cell Adhesion Molecule | 4 | 2017 | 10 | 0.390 |
Why?
| | Receptors, Complement 3b | 2 | 2023 | 82 | 0.380 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1181 | 0.380 |
Why?
| | Female | 22 | 2025 | 68770 | 0.340 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1367 | 0.340 |
Why?
| | Kallikrein-Kinin System | 1 | 2009 | 1 | 0.320 |
Why?
| | Breast Neoplasms | 2 | 2021 | 2142 | 0.320 |
Why?
| | Oxides | 1 | 2009 | 41 | 0.310 |
Why?
| | Arthritis, Experimental | 2 | 2020 | 128 | 0.300 |
Why?
| | Lymphoma, B-Cell | 1 | 2009 | 105 | 0.290 |
Why?
| | Cells, Cultured | 4 | 2023 | 4083 | 0.280 |
Why?
| | Rats | 3 | 2023 | 5499 | 0.270 |
Why?
| | Male | 16 | 2025 | 63674 | 0.270 |
Why?
| | Iron | 1 | 2009 | 288 | 0.270 |
Why?
| | Neoplasms, Experimental | 2 | 2020 | 171 | 0.270 |
Why?
| | Biomimetics | 1 | 2007 | 43 | 0.260 |
Why?
| | Complement Factor H | 2 | 2025 | 72 | 0.260 |
Why?
| | Cholesterol | 2 | 2005 | 412 | 0.260 |
Why?
| | Cations | 3 | 2006 | 80 | 0.250 |
Why?
| | Drug Stability | 4 | 2017 | 159 | 0.230 |
Why?
| | Gentamicins | 1 | 2025 | 54 | 0.230 |
Why?
| | Synovial Membrane | 1 | 2025 | 90 | 0.230 |
Why?
| | Proteomics | 2 | 2021 | 1062 | 0.220 |
Why?
| | Complement C5 | 1 | 2024 | 77 | 0.220 |
Why?
| | Complement C5a | 1 | 2024 | 70 | 0.220 |
Why?
| | Complement Membrane Attack Complex | 1 | 2024 | 37 | 0.220 |
Why?
| | Middle Aged | 6 | 2025 | 31150 | 0.220 |
Why?
| | Complement C3a | 1 | 2024 | 41 | 0.220 |
Why?
| | Cell Adhesion Molecules | 3 | 2014 | 173 | 0.220 |
Why?
| | Half-Life | 2 | 2014 | 162 | 0.220 |
Why?
| | DNA, Recombinant | 1 | 2003 | 46 | 0.210 |
Why?
| | Immunoassay | 1 | 2024 | 107 | 0.210 |
Why?
| | Recombinant Fusion Proteins | 2 | 2023 | 643 | 0.210 |
Why?
| | Polyamines | 3 | 2021 | 39 | 0.210 |
Why?
| | Urinary Tract Infections | 1 | 2025 | 152 | 0.210 |
Why?
| | Ultrasonics | 2 | 2014 | 49 | 0.210 |
Why?
| | DNA | 3 | 2009 | 1400 | 0.200 |
Why?
| | Spermine | 2 | 2005 | 28 | 0.200 |
Why?
| | Pseudomonas Infections | 1 | 2025 | 221 | 0.200 |
Why?
| | Adult | 7 | 2025 | 35572 | 0.200 |
Why?
| | Injections, Intravenous | 2 | 2017 | 201 | 0.190 |
Why?
| | Biological Products | 1 | 2025 | 202 | 0.190 |
Why?
| | Microscopy, Fluorescence | 2 | 2021 | 400 | 0.190 |
Why?
| | Dendrimers | 1 | 2021 | 13 | 0.190 |
Why?
| | Rats, Long-Evans | 1 | 2021 | 134 | 0.180 |
Why?
| | Diffusion | 2 | 2019 | 117 | 0.180 |
Why?
| | Temperature | 2 | 2014 | 636 | 0.180 |
Why?
| | Single-Chain Antibodies | 1 | 2020 | 16 | 0.180 |
Why?
| | Synoviocytes | 1 | 2020 | 10 | 0.180 |
Why?
| | Kupffer Cells | 2 | 2012 | 49 | 0.170 |
Why?
| | Models, Molecular | 3 | 2013 | 1492 | 0.170 |
Why?
| | Dogs | 1 | 2021 | 381 | 0.170 |
Why?
| | Microscopy, Confocal | 1 | 2021 | 310 | 0.170 |
Why?
| | HEK293 Cells | 2 | 2013 | 697 | 0.170 |
Why?
| | Hindlimb | 1 | 2020 | 122 | 0.170 |
Why?
| | Testis | 1 | 2020 | 144 | 0.170 |
Why?
| | Multimodal Imaging | 1 | 2020 | 110 | 0.170 |
Why?
| | Phospholipids | 1 | 2021 | 215 | 0.160 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2020 | 75 | 0.160 |
Why?
| | Hematinics | 1 | 2019 | 19 | 0.160 |
Why?
| | Joints | 1 | 2020 | 100 | 0.160 |
Why?
| | Heterocyclic Compounds, 1-Ring | 1 | 2019 | 4 | 0.160 |
Why?
| | Foot | 1 | 2020 | 93 | 0.160 |
Why?
| | Fluorescein-5-isothiocyanate | 2 | 2009 | 37 | 0.160 |
Why?
| | Carbocyanines | 1 | 2019 | 33 | 0.160 |
Why?
| | Complement C3-C5 Convertases | 1 | 2019 | 21 | 0.160 |
Why?
| | Muscles | 1 | 2020 | 322 | 0.160 |
Why?
| | Magnetics | 2 | 2009 | 44 | 0.160 |
Why?
| | Bone Marrow Cells | 1 | 2020 | 300 | 0.160 |
Why?
| | Jurkat Cells | 1 | 2019 | 134 | 0.160 |
Why?
| | Color | 1 | 2019 | 71 | 0.160 |
Why?
| | Lectins | 1 | 2019 | 46 | 0.160 |
Why?
| | Prostate | 1 | 2020 | 180 | 0.160 |
Why?
| | Molecular Structure | 2 | 2018 | 482 | 0.150 |
Why?
| | Immunity, Innate | 3 | 2023 | 804 | 0.150 |
Why?
| | Opsins | 1 | 2018 | 11 | 0.150 |
Why?
| | Femur | 1 | 2020 | 244 | 0.150 |
Why?
| | Endothelium, Vascular | 2 | 2023 | 901 | 0.150 |
Why?
| | Cell Movement | 1 | 2023 | 945 | 0.150 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 278 | 0.140 |
Why?
| | Proteins | 2 | 2017 | 942 | 0.140 |
Why?
| | Archaeal Viruses | 1 | 2017 | 6 | 0.140 |
Why?
| | Equipment Design | 2 | 2017 | 513 | 0.140 |
Why?
| | Cartilage | 1 | 2019 | 180 | 0.140 |
Why?
| | Drug Liberation | 1 | 2017 | 30 | 0.140 |
Why?
| | MCF-7 Cells | 1 | 2017 | 116 | 0.140 |
Why?
| | Administration, Intravesical | 1 | 2017 | 15 | 0.140 |
Why?
| | Silicon Dioxide | 1 | 2018 | 111 | 0.140 |
Why?
| | Camptothecin | 1 | 2017 | 109 | 0.140 |
Why?
| | Keratins | 1 | 2017 | 175 | 0.140 |
Why?
| | Drug Compounding | 1 | 2017 | 97 | 0.130 |
Why?
| | Optical Imaging | 1 | 2017 | 56 | 0.130 |
Why?
| | Inflammation | 2 | 2024 | 2736 | 0.130 |
Why?
| | Flow Cytometry | 1 | 2020 | 1156 | 0.130 |
Why?
| | Models, Animal | 1 | 2018 | 376 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 187 | 0.130 |
Why?
| | Protein Conformation | 1 | 2019 | 859 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 253 | 0.130 |
Why?
| | Repressor Proteins | 1 | 2019 | 406 | 0.120 |
Why?
| | Swine | 1 | 2018 | 760 | 0.120 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 388 | 0.120 |
Why?
| | Sheep | 1 | 2018 | 837 | 0.120 |
Why?
| | Sodium Hydroxide | 1 | 2014 | 8 | 0.120 |
Why?
| | Complement Pathway, Classical | 1 | 2014 | 18 | 0.120 |
Why?
| | Cross-Linking Reagents | 1 | 2015 | 205 | 0.120 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1717 | 0.120 |
Why?
| | Endocytosis | 1 | 2015 | 163 | 0.110 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2014 | 23 | 0.110 |
Why?
| | Thrombosis | 2 | 2009 | 343 | 0.110 |
Why?
| | Umbilical Veins | 1 | 2014 | 61 | 0.110 |
Why?
| | Antigen-Antibody Reactions | 1 | 2014 | 52 | 0.110 |
Why?
| | Penicillinase | 1 | 2014 | 1 | 0.110 |
Why?
| | Nanoshells | 1 | 2014 | 1 | 0.110 |
Why?
| | Bacillus cereus | 1 | 2014 | 5 | 0.110 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2014 | 25 | 0.110 |
Why?
| | Molecular Imaging | 1 | 2014 | 55 | 0.110 |
Why?
| | Kinetics | 1 | 2017 | 1642 | 0.110 |
Why?
| | Staurosporine | 1 | 2013 | 20 | 0.110 |
Why?
| | Nanocapsules | 1 | 2013 | 10 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 390 | 0.110 |
Why?
| | Cells, Immobilized | 1 | 2013 | 21 | 0.110 |
Why?
| | Models, Biological | 2 | 2019 | 1722 | 0.110 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2013 | 30 | 0.110 |
Why?
| | Lung | 3 | 2018 | 3931 | 0.110 |
Why?
| | Species Specificity | 1 | 2014 | 575 | 0.110 |
Why?
| | Blood Cells | 1 | 2013 | 39 | 0.100 |
Why?
| | Gene Expression | 2 | 2012 | 1472 | 0.100 |
Why?
| | Molecular Conformation | 1 | 2013 | 144 | 0.100 |
Why?
| | Kininogens | 1 | 2012 | 6 | 0.100 |
Why?
| | Iron-Dextran Complex | 1 | 2012 | 7 | 0.100 |
Why?
| | Blood Platelets | 1 | 2015 | 380 | 0.100 |
Why?
| | Protein Kinase C | 1 | 2013 | 259 | 0.100 |
Why?
| | Mannans | 1 | 2012 | 6 | 0.100 |
Why?
| | Mannose-Binding Lectins | 1 | 2012 | 11 | 0.100 |
Why?
| | Lectins, C-Type | 1 | 2012 | 71 | 0.090 |
Why?
| | Pharmaceutical Vehicles | 1 | 2011 | 11 | 0.090 |
Why?
| | High-Energy Shock Waves | 1 | 2011 | 4 | 0.090 |
Why?
| | Mice, Knockout | 2 | 2017 | 2871 | 0.090 |
Why?
| | Collagen Type I | 1 | 2012 | 119 | 0.090 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 1443 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 814 | 0.090 |
Why?
| | Cloning, Molecular | 1 | 2012 | 524 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1928 | 0.090 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2011 | 107 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4063 | 0.080 |
Why?
| | Mice, Transgenic | 2 | 2007 | 2119 | 0.080 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 380 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 840 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2013 | 547 | 0.080 |
Why?
| | Molecular Weight | 1 | 2009 | 332 | 0.080 |
Why?
| | Aged | 2 | 2025 | 22099 | 0.080 |
Why?
| | Nanostructures | 1 | 2009 | 100 | 0.070 |
Why?
| | Bacterial Proteins | 1 | 2014 | 835 | 0.070 |
Why?
| | Phosphatidylcholines | 2 | 2014 | 146 | 0.070 |
Why?
| | Plasma | 1 | 2009 | 206 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2009 | 811 | 0.070 |
Why?
| | United States | 1 | 2024 | 13900 | 0.070 |
Why?
| | Carcinoma | 1 | 2009 | 217 | 0.070 |
Why?
| | Cell Line | 1 | 2012 | 2781 | 0.060 |
Why?
| | CpG Islands | 1 | 2006 | 152 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3408 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 4925 | 0.060 |
Why?
| | Serum Albumin | 1 | 2005 | 149 | 0.060 |
Why?
| | Adjuvants, Immunologic | 1 | 2005 | 221 | 0.060 |
Why?
| | Rheumatoid Factor | 1 | 2025 | 167 | 0.060 |
Why?
| | Micelles | 1 | 2004 | 37 | 0.050 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2005 | 177 | 0.050 |
Why?
| | Heparin | 1 | 2005 | 253 | 0.050 |
Why?
| | Biological Transport, Active | 1 | 2003 | 78 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 3973 | 0.050 |
Why?
| | Luciferases | 1 | 2003 | 148 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 2058 | 0.050 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 548 | 0.050 |
Why?
| | Pseudomonas aeruginosa | 1 | 2025 | 347 | 0.050 |
Why?
| | Mannose-Binding Lectin | 1 | 2021 | 22 | 0.050 |
Why?
| | Glycerophospholipids | 1 | 2001 | 34 | 0.050 |
Why?
| | 3T3 Cells | 1 | 2001 | 153 | 0.050 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2021 | 17 | 0.050 |
Why?
| | Circular Dichroism | 1 | 2001 | 148 | 0.050 |
Why?
| | Peptides | 1 | 2007 | 925 | 0.050 |
Why?
| | Phagocytosis | 1 | 2023 | 362 | 0.050 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 5 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 2001 | 426 | 0.040 |
Why?
| | Trastuzumab | 1 | 2021 | 101 | 0.040 |
Why?
| | Influenza Vaccines | 1 | 2005 | 532 | 0.040 |
Why?
| | Bacteriophage lambda | 1 | 2021 | 88 | 0.040 |
Why?
| | Thymocytes | 1 | 2020 | 33 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 77 | 0.040 |
Why?
| | Luminescent Proteins | 1 | 2001 | 175 | 0.040 |
Why?
| | Mice, Inbred DBA | 1 | 2020 | 188 | 0.040 |
Why?
| | Plasmids | 1 | 2001 | 358 | 0.040 |
Why?
| | Theranostic Nanomedicine | 1 | 2020 | 12 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 101 | 0.040 |
Why?
| | Microspheres | 1 | 2020 | 127 | 0.040 |
Why?
| | Green Fluorescent Proteins | 1 | 2001 | 385 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 288 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2021 | 326 | 0.040 |
Why?
| | Nanotechnology | 1 | 2020 | 122 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 383 | 0.040 |
Why?
| | Apoptosis | 2 | 2020 | 2503 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2001 | 497 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 171 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 141 | 0.040 |
Why?
| | Extremophiles | 1 | 2017 | 2 | 0.040 |
Why?
| | Sulfolobus | 1 | 2017 | 11 | 0.040 |
Why?
| | Immunity | 1 | 2018 | 139 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2025 | 2708 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2017 | 146 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6556 | 0.030 |
Why?
| | Lecithins | 1 | 2014 | 5 | 0.030 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 256 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 345 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 683 | 0.020 |
Why?
| | Phantoms, Imaging | 1 | 2012 | 137 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2535 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 1086 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1119 | 0.020 |
Why?
| | Materials Testing | 1 | 2009 | 347 | 0.020 |
Why?
| | Salmon | 1 | 2006 | 22 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 141 | 0.020 |
Why?
| | Nasal Lavage Fluid | 1 | 2005 | 14 | 0.020 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2006 | 138 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2005 | 31 | 0.020 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2005 | 38 | 0.020 |
Why?
| | Polyelectrolytes | 1 | 2005 | 15 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2005 | 84 | 0.020 |
Why?
| | Spermatozoa | 1 | 2006 | 91 | 0.020 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2005 | 43 | 0.020 |
Why?
| | Gene Transfer Techniques | 1 | 2006 | 163 | 0.010 |
Why?
| | Ceramides | 1 | 2005 | 112 | 0.010 |
Why?
| | Immunity, Mucosal | 1 | 2005 | 94 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1085 | 0.010 |
Why?
| | Genetic Therapy | 1 | 2006 | 292 | 0.010 |
Why?
| | Rabbits | 1 | 2005 | 778 | 0.010 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2005 | 146 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2006 | 610 | 0.010 |
Why?
| | Spleen | 1 | 2005 | 507 | 0.010 |
Why?
| | Cattle | 1 | 2006 | 976 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 644 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2005 | 601 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 10226 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2005 | 2391 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2017 | 0.010 |
Why?
|
|
Simberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|